Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Sheikh S, Lebel E, Trudel S. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. Future Oncol. 2020;16(34):2783–98.
Joseph NS, Tai YT, Anderson KC, Lonial S. Novel approaches to treating relapsed and refractory multiple myeloma with a focus on recent approvals of belantamab mafodotin and selinexor. Clin Pharmacol. 2021;13:169–80.
Becnel MR, Lee HC. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol. 2020;11:2040620720979813.
Demel I, Bago JR, Hajek R, Jelinek T. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021. Br J Haematol. 2021;193(4):705–22.
Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1–7.
Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109.
Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, et al. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):8-17.e6.
Kurtin S. Relapsed or relapsed/refractory multiple myeloma. J Adv Pract Oncol. 2013;4(6 (suppl 1)):5–14.
Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32(2):252–62.
Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia 2022;36:1371–6.
Vaxman I, Abeykoon J, Dispenzieri A, Kumar SK, Buadi F, Lacy MQ, et al. “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. Blood Cancer J. 2021;11(12):196.
Tzogani K, Penttilä K, Lähteenvuo J, Lapveteläinen T, Lopez Anglada L, Prieto C, et al. EMA review of belantamab mafodotin (Blenrep) for the treatment of adult patients with relapsed/refractory multiple myeloma. Oncologist. 2021;26(1):70–6.
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–21.
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021;127(22):4198–212. https://doi.org/10.1002/cncr.33809.
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Pivotal DREAMM-2 study: single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs). American Society for Clinical Oncology (ASCO) Congress; May 29–31; Virtual Scientific Program, 2020.
Alegre A, Benzo Callejo G, Alonso Fernández R, Martínez-López J, Jimenez-Ubieto A, Cuellar C, et al. Compassionate use of belantamab mafodotin for treatment of patients with relapsed/refractory multiple myeloma heavily treated. Span Exp Blood. 2021;138(Supplement 1):3775.
Atieh T, Atrash S, Mohan M, Shune L, Mahmoudjafari Z, Quick J, et al. Belantamab in combination with dexamethasone in patients with triple-class relapsed/refractory multiple myeloma. Blood. 2021;138:1642.
Fazio F, Brescini M, Lapietra G, Petrucci MT. Belantamab mafodotin in heavily treated relapsed/refractory multiple myeloma patients: a case-series from a real-life experience. HemaSphere. 2021;5(SUPPL 1):42.
Hultcrantz M, Anderson LD, Anwer F, Gasparetto C, Kocoglu MH, Lichtman EI, et al. MM-392: belantamab mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): baseline characteristics. Clin Lymphoma Myeloma Leuk. 2021;21:S439–40.
Hultcrantz M, Orozco J, Peterson TJ, Derkach A, Hassoun H, Korde N, et al. Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world experience. Blood. 2021;138:1644.
Shragai T, Magen H, Lavi N, Gatt M, Trestman S, Zektser M, et al. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study. Br J Haematol. 2022. https://doi.org/10.1111/bjh.18479.
Belantamab Eye Care Support Programme (GSK). https://www.blenrephcp.com/safety/ocular-management-support/.
World Medical Association Declaration of Helsinki. ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.
US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 5. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed May 18, 2022.
Hartley-Brown M, Chitty D, Thakur R. Monoclonal antibodies in myeloma: optimizing targeted therapy. Cancer J. 2021;27(3):222–30.
Bladé J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12(3):45.
Hernández-Rivas J-Á, Ríos-Tamayo R, Encinas C, Alonso R, Lahuerta J-J. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res. 2022;10(1):1.
Dhanasiri S, Hollier-Hann G, Stothard C, Dhanda DS, Davies FE, Rodriguez-Otero P. Treatment patterns and outcomes in triple-class exposed patients with relapsed and refractory multiple myeloma: findings from the multinational ITEMISE study. Clin Ther. 2021;43(11):1983-96.e3.
Kostos L, Hong W, Lee B, Tran B, Lok SW, Anton A, et al. Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting. Int J Cancer. 2021;149(2):409–19.
Offidani M, Corvatta L, Morè S, Olivieri A. Belantamab mafodotin for the treatment of multiple myeloma: an overview of the clinical efficacy and safety. Drug Des Dev Ther. 2021;15:2401–15.